Table 1. Patient demographics and baseline characteristics.
| Characteristicsa |
Main study |
PED subgroup |
Switched Treatment |
Discontinued Treatment |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ranibizumab cohort | Aflibercept cohort | P-value | Ranibizumab cohort | Aflibercept cohort | P-value | Ranibizumab cohort | Aflibercept cohort | Ranibizumab cohort | Aflibercept cohort | |
| Number of patients | 2869 | 3630 | 208 | 176 | 847 | 442 | 882 | 697 | ||
| Number (%b) of eyes | 3350 (61.5%) | 4300 (73.5%) | 253 (7.6%) | 203 (4.7%) | 927 (17.0%) | 484 (8.3%) | 955 (17.5%) | 785 (13.4%) | ||
| Agec (years), n (%) | <0.0001 | 0.0001 | ||||||||
| ≤70 | 209 (7.3%) | 298 (8.2%) | 10 (4.8%) | 16 (9.1%) | 91 (10.7%) | 55 (12.4%) | 61 (6.9%) | 43 (6.2%) | ||
| 71–75 | 255 (8.9%) | 382 (10.5%) | 16 (7.7%) | 22 (12.5%) | 101 (11.9%) | 45 (10.2%) | 64 (7.3%) | 62 (8.9%) | ||
| 76–80 | 413 (14.4%) | 638 (17.6%) | 30 (14.4%) | 42 (23.9%) | 135 (15.9%) | 60 (13.6%) | 133 (15.1%) | 112 (16.1%) | ||
| 81–85 | 636 (22.2%) | 863 (23.8%) | 50 (24.0%) | 29 (16.5%) | 192 (22.7%) | 105 (23.8%) | 188 (21.3%) | 159 (22.8%) | ||
| 86–89 | 604 (21.1%) | 726 (20.0%) | 34 (16.3%) | 40 (22.7%) | 159 (18.8%) | 88 (19.9%) | 169 (19.2%) | 131 (18.8%) | ||
| 90+ | 752 (26.2%) | 723 (19.9%) | 68 (32.7%) | 27 (15.3%) | 169 (20.0%) | 89 (20.1%) | 267 (30.3%) | 190 (27.3%) | ||
| Min | 33.0 | 38.0 | 63.0 | 58.0 | 38.0 | 53.0 | 53.0 | 38.0 | ||
| Mean (SD) | 83.4 (8.1) | 82.4 (7.8) | 84.3 (7.1) | 81.5 (7.4) | 81.8 (8.4) | 81.9 (8.5) | 83.4 (7.9) | 83.4 (7.7) | ||
| Female (n, %) | 1887 (65.8%)d | 2312 (63.8%)e | 0.09 | 148 (71.2%) | 102 (58.0%) | 0.007 | 525 (62.5%) | 295 (67.4%) | 528 (63.8%) | 397 (61.8%) |
| Bilateral treatment | 481 (16.8%) | 670 (18.5%) | 0.11 | 45 (21.6%) | 27 (15.3%) | 0.23 | 80 (9.4%) | 42 (9.5%) | 73 (8.3%) | 88 (12.6%) |
| Study eye VA, mean letter score at index (SD) | 57.5 (21.2) | 58.5 (20.7) | 0.025 | 61.9 (18.0) | 61.7 (19.2) | 0.91 | 57.8 (19.8) | 57.8 (19.9) | 49.1 (25.2) | 51.0 (24.5) |
| VA letter score, n (%) | ||||||||||
| ≥70 | 1098 (32.8%) | 1498 (34.8%) | 0.06 | 107 (42.3%) | 89 (43.8%) | 0.74 | 290 (31.3%) | 165 (34.1%) | 237 (24.8%) | 193 (24.4%) |
| ≤35 | 639 (19.1%) | 777 (18.1%) | 0.26 | 27 (10.7%) | 26 (12.8%) | 0.48 | 174 (18.8%) | 93 (19.2%) | 320 (33.5%) | 231 (29.4%) |
| Study eye VA, mean change index to switch (SD) | −1.0 (13.9) | −1.5 (15.2) | ||||||||
a
Baseline VA for all treatment-naive patients (not just those with VA scores at 12 months).
b
Denominator for PED subgroup is eyes in main study. For all other cohorts, denominator is eyes that meet inclusion criteria but with no requirement for 12 months of follow-up or VA at month 12.
c
Age was collected in 5-year bands up until the maximum (90+ years). The midpoint of the band, and 92 for the highest band was used when calculating age descriptive statistics.
d
Gender not known for two patients.
e
Gender not known for five patients.